HUE046508T2 - Orvepitant krónikus viszketés kezelésére - Google Patents

Orvepitant krónikus viszketés kezelésére

Info

Publication number
HUE046508T2
HUE046508T2 HUE13774189A HUE13774189A HUE046508T2 HU E046508 T2 HUE046508 T2 HU E046508T2 HU E13774189 A HUE13774189 A HU E13774189A HU E13774189 A HUE13774189 A HU E13774189A HU E046508 T2 HUE046508 T2 HU E046508T2
Authority
HU
Hungary
Prior art keywords
orvepitant
treatment
chronic pruritus
pruritus
chronic
Prior art date
Application number
HUE13774189A
Other languages
English (en)
Inventor
Ratti Emiliangelo
Trower Michael
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Publication of HUE046508T2 publication Critical patent/HUE046508T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrically Operated Instructional Devices (AREA)
HUE13774189A 2012-10-11 2013-10-09 Orvepitant krónikus viszketés kezelésére HUE046508T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261712499P 2012-10-11 2012-10-11

Publications (1)

Publication Number Publication Date
HUE046508T2 true HUE046508T2 (hu) 2020-03-30

Family

ID=49322388

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13774189A HUE046508T2 (hu) 2012-10-11 2013-10-09 Orvepitant krónikus viszketés kezelésére

Country Status (24)

Country Link
US (3) US9603849B2 (hu)
EP (2) EP2906219B1 (hu)
JP (2) JP6815728B2 (hu)
KR (1) KR102202481B1 (hu)
CN (1) CN104703603A (hu)
AU (1) AU2013328695B9 (hu)
BR (1) BR112015006051A2 (hu)
CA (1) CA2884454C (hu)
CY (1) CY1122313T1 (hu)
DK (1) DK2906219T3 (hu)
EA (1) EA201590364A1 (hu)
ES (1) ES2750662T3 (hu)
HK (1) HK1211486A1 (hu)
HR (1) HRP20191955T1 (hu)
HU (1) HUE046508T2 (hu)
IL (1) IL237636B (hu)
LT (1) LT2906219T (hu)
MX (1) MX362879B (hu)
PL (1) PL2906219T3 (hu)
PT (1) PT2906219T (hu)
RS (1) RS59470B1 (hu)
SG (1) SG11201501867UA (hu)
SI (1) SI2906219T1 (hu)
WO (1) WO2014057003A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX362879B (es) * 2012-10-11 2019-02-21 Nerre Therapeutics Ltd Usos novedosos.
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
RU2746601C2 (ru) * 2016-01-08 2021-04-16 Нерре Терапьютикс Лимитед Орвепитант для лечения хронического кашля
MX2018016400A (es) * 2016-06-29 2019-09-02 Menlo Therapeutics Inc Uso de antagonistas de neuroquinina 1 para tratar una variedad de afecciones pruríticas.
TWI805601B (zh) 2017-08-11 2023-06-21 南韓商愛茉莉太平洋股份有限公司 醫藥組成物及抑制其形成結晶的方法
AU2020341575A1 (en) 2019-09-05 2022-03-24 Incyte Corporation Ruxolitinib formulation for reduction of itch in atopic dermatitis
JP7478894B1 (ja) 2022-11-30 2024-05-07 花王株式会社 痒みの予防又は改善剤
WO2024117173A1 (ja) * 2022-11-30 2024-06-06 花王株式会社 痒みの予防又は改善剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2728265A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
EP1295599A1 (en) 2001-09-21 2003-03-26 Boehringer Ingelheim International GmbH Method for the treatment of prevention of atopic dermatitis
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2006516581A (ja) * 2003-01-27 2006-07-06 グラクソ グループ リミテッド 機能性消化不良を治療するための化学化合物の使用
GB0522061D0 (en) 2005-10-28 2005-12-07 Glaxo Group Ltd Chemical process
CA2708251C (en) * 2007-12-07 2016-04-12 Zymogenetics, Inc. Humanized antibody molecules specific for il-31
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
AU2010217615C1 (en) * 2009-02-24 2013-05-23 Novartis Ag Uses of NK receptor antagonists
JP2014511393A (ja) * 2011-03-07 2014-05-15 セルジーン コーポレイション イソインドリン化合物を用いた疾患の治療方法
JP6111274B2 (ja) 2012-02-22 2017-04-05 レオ ファーマ アクティーゼルスカブ 新規ニューロキニン1受容体アンタゴニスト化合物
MX362879B (es) * 2012-10-11 2019-02-21 Nerre Therapeutics Ltd Usos novedosos.
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus

Also Published As

Publication number Publication date
SG11201501867UA (en) 2015-04-29
CY1122313T1 (el) 2021-01-27
US20150238486A1 (en) 2015-08-27
HRP20191955T1 (hr) 2020-01-24
MX2015004162A (es) 2015-07-06
JP2015533136A (ja) 2015-11-19
AU2013328695B2 (en) 2018-04-05
PL2906219T3 (pl) 2020-02-28
LT2906219T (lt) 2019-10-25
JP6953468B2 (ja) 2021-10-27
ES2750662T3 (es) 2020-03-26
CN104703603A (zh) 2015-06-10
BR112015006051A2 (pt) 2017-07-04
IL237636A0 (en) 2015-04-30
WO2014057003A1 (en) 2014-04-17
CA2884454A1 (en) 2014-04-17
US20190216806A1 (en) 2019-07-18
AU2013328695B9 (en) 2018-05-17
US20170143711A1 (en) 2017-05-25
EA201590364A1 (ru) 2015-11-30
US9603849B2 (en) 2017-03-28
KR20150064732A (ko) 2015-06-11
AU2013328695A9 (en) 2018-04-26
EP2906219A1 (en) 2015-08-19
IL237636B (en) 2019-01-31
EP2906219B1 (en) 2019-08-07
SI2906219T1 (sl) 2019-12-31
MX362879B (es) 2019-02-21
CA2884454C (en) 2021-07-27
PT2906219T (pt) 2019-11-04
HK1211486A1 (en) 2016-05-27
DK2906219T3 (da) 2019-10-28
JP2019131594A (ja) 2019-08-08
KR102202481B1 (ko) 2021-01-12
RS59470B1 (sr) 2019-11-29
EP3597192A1 (en) 2020-01-22
AU2013328695A1 (en) 2015-04-02
JP6815728B2 (ja) 2021-01-20

Similar Documents

Publication Publication Date Title
IL237275A0 (en) Compounds for the treatment of paramoxovirus viral infections
HK1211475A1 (en) Combination therapy
HK1206009A1 (en) Amino-substituted imidazopyridazines
HK1205512A1 (en) Amino-substituted imidazopyridazines
HK1206338A1 (en) Pyrimidine compounds for the treatment of cancer
ZA201906339B (en) Methods for treating pruritus
HK1213544A1 (zh) 新型二環苯基-吡啶/吡嗪用於治療癌症
PT2906219T (pt) Orvepitant para o tratamento do prurido crónico
EP2921510A4 (en) SURFACE TREATMENT COMPOSITION
GB201219873D0 (en) Diverticulitis treatment
EP2925752A4 (en) PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
LT2833884T (lt) Ccr3-inhibitorių panaudojimas
GB201217439D0 (en) Combination therapy
GB201207305D0 (en) Therapy
HK1210426A1 (en) Combination therapy
EP2812190A4 (en) SURFACE TREATMENT COMPOSITION
EP2892529A4 (en) USES OF (-) - PERHEXILINE
PL2948129T3 (pl) Związki terapeutyczne
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
GB201314286D0 (en) Therapeutic Compounds
GB201312499D0 (en) Therapeutic compounds
PL2841079T3 (pl) Nowe kompozycje do leczenia przewlekłych owrzodzeń
GB201320905D0 (en) Therapeutic compounds
IL236873A0 (en) therapeutic compounds
GB201209198D0 (en) Liquid treatment